{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T12:54:17Z","timestamp":1794747257542,"version":"4.9.1"},"reference-count":41,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2020,8,18]],"date-time":"2020-08-18T00:00:00Z","timestamp":1597708800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>RF and ACPA are used as diagnostic tools and their presence has been associated with clinical response to some biologic DMARDs (bDMARDs) in RA. This study compared the impact of seropositivity on drug discontinuation and effectiveness of bDMARDs in patients with RA, using head-to-head comparisons in a real-world setting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a pooled analysis of 16 observational RA registries. Inclusion criteria were a diagnosis of RA, initiation of treatment with rituximab (RTX), abatacept (ABA), tocilizumab (TCZ) or TNF inhibitors (TNFis) and available information on RF and\/or ACPA status. Drug discontinuation was analysed using Cox regression, including drug, seropositivity, their interaction, adjusting for concomitant and past treatments and patient and disease characteristics and accounting for country and calendar year of bDMARD initiation. Effectiveness was analysed using the Clinical Disease Activity Index evolution over time.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among the 27\u00a0583 eligible patients, the association of seropositivity with drug discontinuation differed across bDMARDs (P for interaction &amp;lt;0.001). The adjusted hazard ratios for seropositive compared with seronegative patients were 1.01 (95% CI 0.95, 1.07) for TNFis, 0.89 (0.78, 1.02)] for TCZ, 0.80 (0.72, 0.88) for ABA and 0.70 (0.59, 0.84) for RTX. Adjusted differences in remission and low disease activity rates between seropositive and seronegative patients followed the same pattern, with no difference in TNFis, a small difference in TCZ, a larger difference in ABA and the largest difference in RTX (Lundex remission difference +5.9%, low disease activity difference +11.6%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Seropositivity was associated with increased effectiveness of non-TNFi bDMARDs, especially RTX and ABA, but not TNFis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/rheumatology\/keaa393","type":"journal-article","created":{"date-parts":[[2020,6,10]],"date-time":"2020-06-10T15:16:05Z","timestamp":1591802165000},"page":"820-828","source":"Crossref","is-referenced-by-count":85,"title":["The impact of seropositivity on the effectiveness of biologic anti-rheumatic agents: results from a collaboration of 16 registries"],"prefix":"10.1093","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1956-2607","authenticated-orcid":false,"given":"Delphine S","family":"Courvoisier","sequence":"first","affiliation":[{"name":"Rheumatology, University Hospitals of Geneva, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarina","family":"Chatzidionysiou","sequence":"additional","affiliation":[{"name":"Rheumatology, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Mongin","sequence":"additional","affiliation":[{"name":"Rheumatology, University Hospitals of Geneva, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4315-9009","authenticated-orcid":false,"given":"Kim","family":"Lauper","sequence":"additional","affiliation":[{"name":"Rheumatology, University Hospitals of Geneva, Geneva, Switzerland"},{"name":"Centre for Epidemiology Versus Arthritis, Centre for Musculoskeletal Research, University of Manchester, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Mariette","sequence":"additional","affiliation":[{"name":"Rheumatology, Universit\u00e9 Paris Sud, AP-HP, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Morel","sequence":"additional","affiliation":[{"name":"Rheumatology, CHU and University of Montpellier, Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques-Eric","family":"Gottenberg","sequence":"additional","affiliation":[{"name":"Rheumatology, University Hospital of Strasbourg, Strasbourg, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7136-5248","authenticated-orcid":false,"given":"Sytske Anne","family":"Bergstra","sequence":"additional","affiliation":[{"name":"Rheumatology, Leiden University Medical Center, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel Pombo","family":"Suarez","sequence":"additional","affiliation":[{"name":"Rheumatology, Clinical University Hospital, Santiago de Compostela, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catalin","family":"Codreanu","sequence":"additional","affiliation":[{"name":"Center of Rheumatic Diseases, University of Medicine and Pharmacy, Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tore K","family":"Kvien","sequence":"additional","affiliation":[{"name":"Rheumatology, Diakonhjemmet Hospital, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7946-1365","authenticated-orcid":false,"given":"Maria Jose","family":"Santos","sequence":"additional","affiliation":[{"name":"Rheumatology, Hospital Garcia de Orta, Almada, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karel","family":"Pavelka","sequence":"additional","affiliation":[{"name":"Rheumatology, Charles University, Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merete L","family":"Hetland","sequence":"additional","affiliation":[{"name":"DANBIO Registry and Copenhagen Center for Arthritis Research, Rigshospitalet, Glostrup, Denmark"},{"name":"Clinical Medicine, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Askling","sequence":"additional","affiliation":[{"name":"Clinical Epidemiology, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3805-2290","authenticated-orcid":false,"given":"Carl","family":"Turesson","sequence":"additional","affiliation":[{"name":"Rheumatology, Sk\u00e5ne University Hospital, Malm\u00f6, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Kubo","sequence":"additional","affiliation":[{"name":"First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0807-7139","authenticated-orcid":false,"given":"Yoshiya","family":"Tanaka","sequence":"additional","affiliation":[{"name":"First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0474-5344","authenticated-orcid":false,"given":"Florenzo","family":"Iannone","sequence":"additional","affiliation":[{"name":"Italian Group for the Study of Early Arthritis, University Hospital of Bari, Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Choquette","sequence":"additional","affiliation":[{"name":"Institut de Recherche en Rhumatologie de Montr\u00e9al, Centre hospitalier de l'Universit\u00e9 de Montr\u00e9al and Universit\u00e9 de Montr\u00e9al, Montr\u00e9al, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan C","family":"Nordstr\u00f6m","sequence":"additional","affiliation":[{"name":"ROB-FIN Registry, Helsinki University Hospital and Helsinki University, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziga","family":"Rotar","sequence":"additional","affiliation":[{"name":"Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Galina","family":"Lukina","sequence":"additional","affiliation":[{"name":"Rheumatology, V. A. Nasonova Research Institute of Rheumatology, Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cem","family":"Gabay","sequence":"additional","affiliation":[{"name":"Rheumatology, University Hospitals of Geneva, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Van Vollenhoven","sequence":"additional","affiliation":[{"name":"Rheumatology and Clinical Immunology, Amsterdam University Medical Centers, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Finckh","sequence":"additional","affiliation":[{"name":"Rheumatology, University Hospitals of Geneva, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,8,18]]},"reference":[{"key":"2021020119063755600_keaa393-B1","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/BOR.0000000000000356","article-title":"Anticitrullinated protein antibodies: origin and role in the pathogenesis of rheumatoid arthritis","volume":"29","author":"England","year":"2017","journal-title":"Curr Opin Rheumatol"},{"key":"2021020119063755600_keaa393-B2","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1016\/S0140-6736(17)31472-1","article-title":"Pathogenetic insights from the treatment of rheumatoid arthritis","volume":"389","author":"McInnes","year":"2017","journal-title":"Lancet"},{"key":"2021020119063755600_keaa393-B3","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.berh.2014.10.016","article-title":"Seronegative rheumatoid arthritis: pathogenetic and therapeutic aspects","volume":"28","author":"Pratt","year":"2014","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"2021020119063755600_keaa393-B4","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1136\/ard.62.9.835","article-title":"Quantification of the influence of cigarette smoking on rheumatoid arthritis: results from a population based case-control study, using incident cases","volume":"62","author":"Stolt","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"2021020119063755600_keaa393-B5","doi-asserted-by":"crossref","first-page":"26021","DOI":"10.1038\/srep26021","article-title":"Analysis of serum immune markers in seropositive and seronegative rheumatoid arthritis and in high-risk seropositive arthralgia patients","volume":"6","author":"Chalan","year":"2016","journal-title":"Sci Rep"},{"key":"2021020119063755600_keaa393-B6","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.3899\/jrheum.140082","article-title":"Prognosis of seronegative patients in a large prospective cohort of patients with early inflammatory arthritis","volume":"41","author":"Barra","year":"2014","journal-title":"J Rheumatol"},{"key":"2021020119063755600_keaa393-B7","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1007\/s00296-015-3271-8","article-title":"Associations of rheumatoid factor and anti-citrullinated peptide antibody with disease progression and treatment outcomes in patients with rheumatoid arthritis","volume":"35","author":"Katchamart","year":"2015","journal-title":"Rheumatol Int"},{"key":"2021020119063755600_keaa393-B8","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1093\/rheumatology\/kei203","article-title":"Anti-CCP antibodies measured at disease onset help identify seronegative rheumatoid arthritis and predict radiological and functional outcome","volume":"45","author":"Quinn","year":"2006","journal-title":"Rheumatology (Oxford)"},{"key":"2021020119063755600_keaa393-B9","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1093\/rheumatology\/keu390","article-title":"Patients receiving anti-TNF therapies experience clinically important improvements in RA-related fatigue: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis","volume":"54","author":"Druce","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"2021020119063755600_keaa393-B10","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.imlet.2017.05.010","article-title":"Biomarkers for rheumatoid arthritis: from molecular processes to diagnostic applications-current concepts and future perspectives","volume":"189","author":"Nakken","year":"2017","journal-title":"Immunol Lett"},{"key":"2021020119063755600_keaa393-B11","doi-asserted-by":"crossref","first-page":"e000406","DOI":"10.1136\/rmdopen-2016-000406","article-title":"Diagnosis, prognosis and classification of early arthritis: results of a systematic review informing the 2016 update of the EULAR recommendations for the management of early arthritis","volume":"3","author":"Hua","year":"2017","journal-title":"RMD Open"},{"key":"2021020119063755600_keaa393-B12","doi-asserted-by":"crossref","first-page":"e89442","DOI":"10.1371\/journal.pone.0089442","article-title":"The status of rheumatoid factor and anti-cyclic citrullinated peptide antibody are not associated with the effect of anti-TNF\u03b1 agent treatment in patients with rheumatoid arthritis: a meta-analysis","volume":"9","author":"Lv","year":"2014","journal-title":"PLoS One"},{"key":"2021020119063755600_keaa393-B13","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1136\/annrheumdis-2015-207760","article-title":"Effectiveness of tocilizumab with and without synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis: results from a European collaborative study","volume":"75","author":"Gabay","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2021020119063755600_keaa393-B14","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.semarthrit.2017.03.024","article-title":"III. Tocilizumab treatment leads to improvement in disease activity regardless of CCP status in rheumatoid arthritis","volume":"47","author":"Cappelli","year":"2017","journal-title":"Semin Arthritis Rheum"},{"key":"2021020119063755600_keaa393-B15","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1002\/art.39595","article-title":"Brief report: association of rheumatoid factor and anti-citrullinated protein antibody positivity with better effectiveness of abatacept: results from the Pan-European Registry analysis","volume":"68","author":"Gottenberg","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2021020119063755600_keaa393-B16","doi-asserted-by":"crossref","first-page":"3681","DOI":"10.1002\/art.30596","article-title":"Inflammation and autoantibody markers identify rheumatoid arthritis patients with enhanced clinical benefit following rituximab treatment","volume":"63","author":"Lal","year":"2011","journal-title":"Arthritis Rheum"},{"key":"2021020119063755600_keaa393-B17","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1007\/s00296-016-3506-3","article-title":"Anti-citrullinated peptide antibodies and their value for predicting responses to biologic agents: a review","volume":"36","author":"Martin-Mola","year":"2016","journal-title":"Rheumatol Int"},{"key":"2021020119063755600_keaa393-B18","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1136\/ard.2010.148759","article-title":"Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries","volume":"70","author":"Chatzidionysiou","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"2021020119063755600_keaa393-B19","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1093\/rheumatology\/kep314","article-title":"Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis","volume":"48","author":"Quartuccio","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"2021020119063755600_keaa393-B20","doi-asserted-by":"crossref","first-page":"240","DOI":"10.3899\/jrheum.110610","article-title":"Effectiveness of rituximab in patients with rheumatoid arthritis: observational study from","volume":"39","author":"Soliman","year":"2012","journal-title":"J Rheumatol"},{"key":"2021020119063755600_keaa393-B21","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1136\/annrheumdis-2013-203993","article-title":"Rituximab versus an alternative TNF inhibitor in patients with rheumatoid arthritis who failed to respond to a single previous TNF inhibitor: SWITCH-RA, a global, observational, comparative effectiveness study","volume":"74","author":"Emery","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2021020119063755600_keaa393-B22","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1136\/annrheumdis-2011-201109","article-title":"Positivity for anti-cyclic citrullinated peptide is associated with a better response to abatacept: data from the \u2018Orencia and Rheumatoid Arthritis\u2019 registry","volume":"71","author":"Gottenberg","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"2021020119063755600_keaa393-B23","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1007\/s40265-017-0775-4","article-title":"Abatacept: a review in rheumatoid arthritis","volume":"77","author":"Blair","year":"2017","journal-title":"Drugs"},{"key":"2021020119063755600_keaa393-B24","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.semarthrit.2012.11.007","article-title":"Rheumatoid factor as predictor of response to abatacept, rituximab and tocilizumab in rheumatoid arthritis: systematic review and meta-analysis","volume":"43","author":"Maneiro","year":"2013","journal-title":"Semin Arthritis Rheum"},{"key":"2021020119063755600_keaa393-B25","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1136\/annrheumdis-2015-207784","article-title":"Comparison of the efficacies of abatacept and tocilizumab in patients with rheumatoid arthritis by propensity score matching","volume":"75","author":"Kubo","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2021020119063755600_keaa393-B26","doi-asserted-by":"crossref","first-page":"162","DOI":"10.3899\/jrheum.160460","article-title":"Rituximab retreatment in rheumatoid arthritis in a real-life cohort: data from the CERERRA Collaboration","volume":"44","author":"Chatzidionysiou","year":"2017","journal-title":"J Rheumatol"},{"key":"2021020119063755600_keaa393-B27","doi-asserted-by":"crossref","first-page":"e000040","DOI":"10.1136\/rmdopen-2014-000040","article-title":"The impact of patient heterogeneity and socioeconomic factors on abatacept retention in rheumatoid arthritis across nine European countries","volume":"1","author":"Finckh","year":"2015","journal-title":"RMD Open"},{"key":"2021020119063755600_keaa393-B28","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1136\/annrheumdis-2017-212845","article-title":"Comparative effectiveness of tocilizumab versus TNF inhibitors as monotherapy or in combination with conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis after the use of at least one biologic disease-modifying antirheumatic drug: analyses from the pan-European TOCERRA register collaboration","volume":"77","author":"Lauper","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2021020119063755600_keaa393-B29","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1002\/art.21570","article-title":"The LUNDEX, a new index of drug efficacy in clinical practice: results of a five-year observational study of treatment with infliximab and etanercept among rheumatoid arthritis patients in southern Sweden","volume":"54","author":"Kristensen","year":"2006","journal-title":"Arthritis Rheum"},{"key":"2021020119063755600_keaa393-B30","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1136\/annrheumdis-2018-214968","article-title":"When binary and continuous responses disagree","volume":"79","author":"Ouyang","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2021020119063755600_keaa393-B31","doi-asserted-by":"crossref","first-page":"e39","DOI":"10.1136\/annrheumdis-2019-215019","article-title":"Response to: \u2018When binary and continuous responses disagree\u2019 by Dr Ouyang","volume":"79","author":"Lauper","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2021020119063755600_keaa393-B32","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1093\/aje\/kwm223","article-title":"A modified least-squares regression approach to the estimation of risk difference","volume":"166","author":"Cheung","year":"2007","journal-title":"Am J Epidemiol"},{"key":"2021020119063755600_keaa393-B33","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1002\/art.21650","article-title":"Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse","volume":"54","author":"Cambridge","year":"2006","journal-title":"Arthritis Rheum"},{"key":"2021020119063755600_keaa393-B34","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.jval.2017.05.020","article-title":"Cost-effectiveness analysis of abatacept compared with adalimumab on background methotrexate in biologic-naive adult patients with rheumatoid arthritis and poor prognosis","volume":"21","author":"Alemao","year":"2018","journal-title":"Value Health"},{"key":"2021020119063755600_keaa393-B35","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s40744-019-00174-7","article-title":"Efficacy of abatacept and adalimumab in patients with early rheumatoid arthritis with multiple poor prognostic factors: post hoc analysis of a randomized controlled clinical trial (AMPLE)","volume":"6","author":"Fleischmann","year":"2019","journal-title":"Rheumatol Ther"},{"key":"2021020119063755600_keaa393-B36","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1007\/s10067-019-04449-w","article-title":"Predictors of abatacept retention over 2 years in patients with rheumatoid arthritis: results from the real-world ACTION study","volume":"38","author":"Alten","year":"2019","journal-title":"Clin Rheumatol"},{"key":"2021020119063755600_keaa393-B37","first-page":"1234","article-title":"Shared epitope positivity is related to efficacy of abatacept in rheumatoid arthritis","volume":"77","author":"Oryoji","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2021020119063755600_keaa393-B38","doi-asserted-by":"crossref","first-page":"e000742","DOI":"10.1136\/rmdopen-2018-000742","article-title":"Treatment outcomes in patients with seropositive versus seronegative rheumatoid arthritis in phase III randomised clinical trials of tofacitinib","volume":"5","author":"Bird","year":"2019","journal-title":"RMD Open"},{"key":"2021020119063755600_keaa393-B39","doi-asserted-by":"crossref","first-page":"32","DOI":"10.3899\/jrheum.170007","article-title":"Effect of anticitrullinated protein antibody status on response to abatacept or antitumor necrosis factor-\u03b1 therapy in patients with rheumatoid arthritis: a US National Observational Study","volume":"45","author":"Harrold","year":"2018","journal-title":"J Rheumatol"},{"key":"2021020119063755600_keaa393-B40","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1007\/s10067-019-04626-x","article-title":"Association between seropositivity and discontinuation of tumor necrosis factor inhibitors due to ineffectiveness in rheumatoid arthritis","volume":"38","author":"Ogawa","year":"2019","journal-title":"Clin Rheumatol"},{"key":"2021020119063755600_keaa393-B41","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1093\/rheumatology\/kev019","article-title":"Effectiveness of biologic DMARDs in monotherapy versus in combination with synthetic DMARDs in rheumatoid arthritis: data from the Swiss Clinical Quality Management Registry","volume":"54","author":"Gabay","year":"2015","journal-title":"Rheumatology (Oxford)"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/60\/2\/820\/36167693\/keaa393.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/60\/2\/820\/36167693\/keaa393.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,2]],"date-time":"2021-02-02T22:46:30Z","timestamp":1612305990000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/60\/2\/820\/5894051"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,18]]},"references-count":41,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,8,18]]},"published-print":{"date-parts":[[2021,2,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keaa393","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,2,1]]},"published":{"date-parts":[[2020,8,18]]}}}